WELCOME TO THE OFFICIAL AB-DIRECT WEBSITE
We hope that you can find here useful information about the IMI2 supported AB-DIRECT programme aiming at assessing penetration of novel antibiotic gepotidacin into tonsillar and prostate tissue.
Poster presented at the 34th ECCMID congress in Barcelona (May 2024) - Plasma and prostatic tissue phamarcokinetics of gepotidacin in patients undergoing prostatectomy : an ex vivo microdialysis study
Poster presented at the 34th ECCMID congress in Barcelona (May 2024) - Development and validation of a PBPK model of gepotidacinin rats to predict exposure in human prostate
Gepotidacin is a novel antibiotic currently under development. The objective of the project is to explore a potential new option for the treatment of pharyngeal Neisseria gonorrhoeae infections or prostatitis caused by Escherichia coli by demonstrating adequate penetration of a novel antibiotic in tonsillar and prostate tissues.
This AB-DIRECT project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853976. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.